Literature DB >> 16904451

Prostate volume and prostate-specific antigen levels in men enrolled in a large screening trial.

Paul F Pinsky1, Barnett S Kramer, E David Crawford, Robert L Grubb, Donald A Urban, Gerald L Andriole, David Chia, David L Levin, John K Gohagan.   

Abstract

OBJECTIVES: Prostate volume correlates both with prostate-specific antigen (PSA) values and with the presence of benign prostatic hyperplasia (BPH). Here we examine the relationship between prostate volume and PSA level in a large, geographically diverse sample of men undergoing prostate cancer screening.
METHODS: We followed 35,323 men enrolled in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial. Each man was screened with digital rectal examination (DRE) and PSA levels for up to 4 years. Prostate volume was estimated by DRE performed by trained examiners at the PLCO sites. Linear and logistic regression was used to assess the effect of prostate volume and age on PSA levels. Regression coefficients were adjusted for the effect of prostate volume measurement error.
RESULTS: Prostate volume estimated by DRE showed considerable measurement error. Averaging volume over screening visits and accounting for examiner bias greatly reduced this error. Linear regression analysis showed a slope of 0.030/cm3 of log PSA on prostate volume when correcting for measurement error (95% confidence interval [CI], 0.029 to 0.031). Age was independently associated with (log) PSA, with a slope of 0.022 per year. Logistic regression analysis of the risk of having an elevated PSA value (exceeding 4 ng/mL) showed an odds ratio of 1.9 (95% CI, 1.8 to 2.0) associated with a 10 cm3 increase in prostate volume. The correlation of log PSA and prostate volume was 0.37. Prostate volume was not correlated with body mass index and showed weak correlation (r = 0.14) with age.
CONCLUSIONS: Prostate volume and age are independently associated with increased PSA levels in a population of men undergoing screening.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16904451     DOI: 10.1016/j.urology.2006.02.026

Source DB:  PubMed          Journal:  Urology        ISSN: 0090-4295            Impact factor:   2.649


  24 in total

Review 1.  An overview of prostate diseases and their characteristics specific to Asian men.

Authors:  Shu-Jie Xia; Di Cui; Qi Jiang
Journal:  Asian J Androl       Date:  2012-02-06       Impact factor: 3.285

2.  Diagnostic value of MRI-based PSA density in predicting transperineal sector-guided prostate biopsy outcomes.

Authors:  Findlay MacAskill; Su-Min Lee; David Eldred-Evans; Wahyu Wulaningsih; Rick Popert; Konrad Wolfe; Mieke Van Hemelrijck; Giles Rottenberg; Sidath H Liyanage; Peter Acher
Journal:  Int Urol Nephrol       Date:  2017-05-05       Impact factor: 2.370

Review 3.  Biomarker research in prostate cancer--towards utility, not futility.

Authors:  Sheng Fei Oon; Stephen R Pennington; John M Fitzpatrick; R William G Watson
Journal:  Nat Rev Urol       Date:  2011-03       Impact factor: 14.432

4.  Non-steroidal anti-inflammatory drug use and the risk of benign prostatic hyperplasia-related outcomes and nocturia in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial.

Authors:  Siobhan Sutcliffe; Robert L Grubb Iii; Elizabeth A Platz; Lawrence R Ragard; Thomas L Riley; Sally S Kazin; Richard B Hayes; Ann W Hsing; Gerald L Andriole
Journal:  BJU Int       Date:  2012-03-19       Impact factor: 5.588

5.  CCL11 (eotaxin-1): a new diagnostic serum marker for prostate cancer.

Authors:  Manisha Agarwal; Chang He; Javed Siddiqui; John T Wei; Jill A Macoska
Journal:  Prostate       Date:  2012-10-11       Impact factor: 4.104

6.  Dietary carbohydrate, glycemic index, glycemic load, and risk of prostate cancer in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial (PLCO) cohort.

Authors:  James M Shikany; Andrew P Flood; Cari M Kitahara; Ann W Hsing; Tamra E Meyer; Bradley J Willcox; David T Redden; Regina G Ziegler
Journal:  Cancer Causes Control       Date:  2011-05-07       Impact factor: 2.506

7.  Does an asymmetric lobe in digital rectal examination include any risk for prostate cancer? results of 1495 biopsies.

Authors:  Ömer Yilmaz; Özgür Kurul; Ferhat Ates; Hasan Soydan; Zeki Aktas
Journal:  Int Braz J Urol       Date:  2016 Jul-Aug       Impact factor: 1.541

Review 8.  Aberrant PSA glycosylation--a sweet predictor of prostate cancer.

Authors:  Sarah Gilgunn; Paul J Conroy; Radka Saldova; Pauline M Rudd; Richard J O'Kennedy
Journal:  Nat Rev Urol       Date:  2013-01-15       Impact factor: 14.432

9.  Does prostate growth confound prostate specific antigen velocity? Data from the Baltimore longitudinal study of aging.

Authors:  Stacy Loeb; Anna Kettermann; H Ballentine Carter; Luigi Ferrucci; E Jeffrey Metter; Patrick C Walsh
Journal:  J Urol       Date:  2008-08-15       Impact factor: 7.450

10.  Serum prostate-specific antigen as a predictor of prostate volume and lower urinary tract symptoms in a community-based cohort: a large-scale Korean screening study.

Authors:  Dong Soo Park; Jong Jin Oh; Jae Yup Hong; Young Kwon Hong; Don Kyung Choi; In Hyuck Gong; Jin Ho Hwang; Sung Won Kwon
Journal:  Asian J Androl       Date:  2013-01-28       Impact factor: 3.285

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.